Active Biotech AB: Business description, financial summary, 3yr and interim financials, key statistics/ratios and historical ratio analysis.
Provider: Reuters Investment Profile
Provider: MarketLine (a Datamonitor Company)
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Active Biotech AB Receives Warning from Disciplinary Committee of NASDAQ OMX
Active Biotech AB announced that the Disciplinary Committee of NASDAQ OMX have given the Company a warning for violation of stock exchange's regulations for issuers for disclosure to the stock market. The case concerns disclosure of information relating to the yet unregistered drug laquinimod.
Latest Developments for Active Biotech AB
- Active Biotech AB and Teva Pharmaceutical Industries Ltd Announce Post-Hoc Analyses of Phase III ALLEGRO and BRAVO Studies
- Active Biotech AB and Teva Pharmaceutical Industries Ltd Publish Pre-Planned Analysis of Phase III ALLEGRO Study
- Active Biotech AB to Present Further Analysis Supporting Effect of ANYARA in Biomarker Defined Subgroup
- Active Biotech AB and Teva Pharmaceutical Industries Ltd Announce Positive Results from Phase IIa Study of Laquinimod in Active Lupus Nephritis
Latest Key Developments in Biotechnology
- Dyax Corp receives orphan drug designation from the U.S. FDA for DX-2930 in hereditary angioedema
- Genmab to be included in OMXC20CAP and OMXC20 indexes-Reuters
- Immunicum AB announces positive results for cancer vaccine INTUVAX in treatment of kidney cancer
- Zealand Pharma says data presented by Sanofi support flexibility in timing of administration for Lyxumia
- Share this
- Digg this